Senti Biosciences develops proprietary Gene Circuits using synthetic biology to reprogram cells for targeted cancer therapies, enabling precise elimination of cancer cells while sparing healthy tissue. Their lead product candidate, SENTI-202, is designed for the treatment of acute myeloid leukemia, addressing the need for more effective and specific cancer treatments.
Funding
$47.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CPFounders
Product
Problem
Current cancer treatments often lack the specificity needed to target cancer cells effectively, leading to damage of healthy tissue and severe side effects for patients. This lack of precision limits the effectiveness of therapies and reduces the overall quality of life for individuals undergoing treatment.
Solution
Senti Biosciences is developing a new generation of cell therapies using synthetic biology and proprietary Gene Circuits to reprogram cells. These Gene Circuits, constructed from novel DNA sequences, enable the therapeutics to sense inputs, compute decisions, and respond dynamically within the cellular environment. By programming cells with biological logic, Senti Bio's approach aims to create cancer therapeutics that precisely target and eliminate cancer cells while sparing healthy tissue and controlling drug expression. Their lead product candidate, SENTI-202, is currently in clinical trials for the treatment of acute myeloid leukemia (AML).
Target Audience
The primary target audience includes patients with various forms of cancer, such as acute myeloid leukemia, hepatocellular carcinoma, and other solid tumors and blood cancers, as well as those with eye, CNS, and liver diseases.
Features
- Gene Circuit technology platform for programming cells with synthetic biology
- Off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells for enhanced targeting
- SENTI-202 product candidate targeting CD33 and/or FLT3 for AML and other blood cancers
- SENTI-301A/SN301A product candidate targeting GPC3 for hepatocellular carcinoma (HCC) and other solid tumors (partnered with Celest Therapeutics)
- Multiple gene therapy programs for eye, CNS, and liver diseases (partnered with Spark Therapeutics)
- Multiple iPSC cell therapy programs for regenerative medicine (partnered with BlueRock Therapeutics)